Inventiva

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-12-09 am EST			5-day change	1st Jan Change
3.640 ^EUR	+4.00%		-1.09%	+66.97%

Nov. 28	JP Morgan Chase Surpasses 5% Stake in Inventiva
Nov. 24	Inventiva Well-Positioned Following Treasury Update

Full Exercise of Option for Inventiva's ADS Offering

Vincent Gallet

Published on 11/17/2025 at 05:00 am EST

- Translated by Marketscreener - See original

Inventiva

+4.00%

NASDAQ Composite

+0.13%

Inventiva has announced that the bookrunners associated with its previously announced U.S. public offering of 38,961,038 American Depositary Shares (ADS) have fully exercised their option to purchase an additional 5,844,155 ADS.

This brings the total number of ADS issued in the offering to 44,805,193, representing estimated net proceeds of approximately $161.2 million. The biopharmaceutical company's ADS are listed for trading on the Nasdaq Global Market.

Settlement and delivery of these additional ADS are expected to take place on November 18. The company intends to use the net proceeds from the sale of the additional ADS on a pro rata basis, consistent with the planned use of net proceeds from the initial offering.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	INVENTIVA	3.640EUR	+4.00%	-1.09%	777M
	NASDAQ COMPOSITE	23,576.49PTS	+0.13%	+0.70%	-

Latest news about Inventiva

Nov. 28	JP Morgan Chase Surpasses 5% Stake in Inventiva
Nov. 24	Inventiva Well-Positioned Following Treasury Update
Nov. 24	KBC Maintains "Buy" Rating on Inventiva, Lowers Target Price
Nov. 20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Nov. 17	Inventiva Boosts ADS Offering to $172 Million	MT
Nov. 17	Full Exercise of Option for Inventiva's ADS Offering
Nov. 14	French and Benelux stocks-Factors to watch	RE
Nov. 13	Inventiva announces trading resumption of its ordinary shares on Euronext Paris	RE
Nov. 13	Inventiva Resumes Trading on Euronext Paris	MT
Nov. 13	France's Inventiva Prices, Upsizes $150 Million American Depositary Shares Offering	MT
Nov. 13	Inventiva announces trading resumption on Euronext Paris	RE
Nov. 13	Inventiva Sets Terms for U.S. ADS Offering
Nov. 13	KBC Welcomes Inventiva's Fundraising Initiative
Nov. 13	Inventiva Shares Pause Trading on Euronext Paris	MT
Nov. 13	Inventiva Temporarily Suspends Trading on Euronext Paris
Nov. 13	Inventiva Seeks $125 Million from US Public Offering of American Depositary Shares	MT
Nov. 06	Wolfe Research Initiates Coverage on Inventiva SA ADR With Outperform Rating	MT
Oct. 15	Inventiva Plans Up to $100 Million At-the-market Share Issuance Program	MT
Oct. 14	Inventiva Files $300 Million Mixed Shelf	MT
Oct. 14	Inventiva SA files for stock shelf of up to $300 million	RE
Oct. 14	Inventiva announces the implementation of a new ATM program	RE
Oct. 14	European Equities Traded in the US as American Depositary Receipts Edge Lower Tuesday	MT
Oct. 09	Inventiva S.A. - Analyst/Investor Day
Oct. 01	France's Inventiva Names New CEO	MT
Oct. 01	Inventiva appoints Andrew Obenshain as chief executive officer	RE

Chart Inventiva

Duration

Period

IVA: Dynamic Chart

Company Profile

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jan. 06 - MASH TAG Scientific Conference

More about the company